Recombinant CCR4 (Mogamulizumab Biosimilar) anticorps

N° du produit ABIN7072382

L’anticorps Lapin Chimeric anti-CCR4 (Mogamulizumab Biosimilar) a été validé pour Dep. Il convient pour détecter CCR4 (Mogamulizumab Biosimilar) dans des échantillons de Humain.

Aperçu rapide pour Recombinant CCR4 (Mogamulizumab Biosimilar) anticorps (ABIN7072382)

Antigène: CCR4 (Mogamulizumab Biosimilar)

Type d'anticorp: Recombinant Antibody

Reactivité: Humain

Hôte: Lapin

Clonalité: Chimeric

Conjugué: Cet anticorp CCR4 (Mogamulizumab Biosimilar) est non-conjugé

Application: Depletion (Dep)

Clone: KW-0761

Détail du produit anti-CCR4 (Mogamulizumab Biosimilar) anticorps

Fonction: Anti-CCR4 [KW-0761 (Mogamulizumab)], Rabbit IgG, kappa

Specificité: This antibody is specific for human CCR4, a chemokine receptor that is preferentially expressed by Th2 and regulatory T (Treg) cells. CCR4 is also detected on basophils, platelets, monocytes and brain microvascular and coronary artery endothelial cells.

Attributs du produit:

Original Species of Ab: Human

Original Format of Ab: IgG1

Purification: Protein A affinity purified

Immunogène: This antibody was prepared by humanization of a mouse anti-CCR4 mAb.

Isotype: IgG kappa

Information d'application

Indications d'application: The clinically used format of this antibody (which underwent additional de-fucosylation to increase antibody-dependent cellular cytotoxicity (ADCC)), has significant clinical activity in heavily pretreated patients with mycosis fungoides and Sézary syndrome, and is associated with an overall response rate of 36.8 % and a median duration of response of 10.4 months (Duvic et al, 2014). It was shown to CCR4-expressing cells by antibody-dependent, cell-mediated cytotoxicity (ADCC). Therapeutically, this results in a dual mechanism of action, in addition to directly targeting malignant T cells over-expressing CCR4, this antibody also depletes T reg cells, an important therapeutic target in human cancers. This antibody is well-tolerated, and administration does not appear to trigger clinically significant autoimmune complications in phase 1/2 trials (Duvic et al, 2014). This antibody has been approved in Japan for the treatment of relapsed or refractory adult T-cell leukemia/lymphoma, and is in clinical trials for solid cancers. For the avoidance of doubt - the material produced by Absolute Antibody has not been de-fucosylated.

Commentaires:

This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques.

Restrictions: For Research Use only

Stockage

Concentration: 1 mg/mL

Buffer: PBS with 0.02 % Proclin 300.

Agent conservateur: ProClin

Précaution d'utilisation: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C,-20 °C

Stockage commentaire: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

Détails sur CCR4 (Mogamulizumab Biosimilar)

Antigène: CCR4 (Mogamulizumab Biosimilar)

Classe de substances: Biosimilar

Sujet: CD194, CKR-4, CCR-4, CCR4, K5-5

UniProt: P51679